SCF BIOMARKER PANEL — THOGALINEX™ (Glioblastoma Endpoint Validation Suite)

API Code: SCF-API-TGX-0001-GBM

Framework: SCF Multi-Omic Endpoint Validation System

Indication: Glioblastoma (GBM)

I. PANEL OBJECTIVE

To establish a multi-layered, SCF-aligned biomarker system enabling:

Quantitative validation of tumor regression and pathway inhibition
Real-time monitoring of metabolic collapse and resistance suppression
Assessment of tumor–neural microenvironment decoupling
FDA-aligned clinical endpoint substantiation (PFS, OS, radiographic response)

II. SCF BIOMARKER ARCHITECTURE (MULTI-OMIC LAYERS)

Layer	Function	Endpoint Role
Genomic	Mutation & tumor driver profiling	Patient stratification
Transcriptomic	Gene expression modulation	Early response detection
Proteomic	Pathway activity	Mechanistic validation
Metabolomic	Energy collapse & flux	Core efficacy signal
Epigenomic	Tumor plasticity	Resistance monitoring
Imaging	Structural tumor response	Primary clinical endpoint
Neurofunctional	Tumor–brain interaction	Functional recovery
Immunologic	Microenvironment modulation	Adjunct efficacy

Aligned with SCF Pathophysiology multi-omic integration model

III. CORE GLIOBLASTOMA BIOMARKER PANEL

A. GENOMIC BIOMARKERS (Patient Stratification & Response Prediction)

Biomarker	Target	SCF Role	Endpoint Utility
EGFR amplification (EGFRvIII)	Proliferation driver	Target validation	Predict response to pathway inhibition
PTEN loss	PI3K activation	Resistance node	Stratify metabolic dependency
IDH1/2 mutation	Metabolic reprogramming	Metabolic subtype	Prognostic + response modifier
MGMT promoter methylation	DNA repair	Sensitivity marker	Predict chemo-sensitivity synergy

B. TRANSCRIPTOMIC BIOMARKERS (Dynamic Response Layer)

Biomarker	Pathway	SCF Function	Endpoint
mTOR expression	Growth signaling	Target suppression	Early efficacy signal
HIF-1α	Hypoxia/angiogenesis	Tumor stress response	Anti-angiogenic validation
VEGF mRNA	Angiogenesis	Tumor vascular activity	Response to anti-angiogenic action
MYC expression	Proliferation	Growth driver	Tumor suppression tracking

C. PROTEOMIC BIOMARKERS (Mechanistic Validation Core)

Biomarker	Pathway	SCF Axis	Endpoint
p-AKT / p-mTOR	PI3K–AKT–mTOR	Axis 1 (signaling)	Primary pharmacodynamic marker
VEGF protein	Angiogenesis	Axis 3	Anti-angiogenic validation
NF-κB (p65)	Inflammation	Axis 1/3	Microenvironment suppression
BDNF	Neuroprotection	Safety axis	Neural preservation
Caspase-3	Apoptosis	Cytotoxic axis	Tumor cell death confirmation

D. METABOLOMIC BIOMARKERS (PRIMARY EFFICACY SIGNAL)

Biomarker	Function	SCF Role	Endpoint
ATP levels	Cellular energy	Metabolic collapse	Core efficacy biomarker
Lactate	Warburg effect	Tumor metabolism	Decrease indicates reversal
NAD+/NADH ratio	Redox state	Mitochondrial function	Restoration signal
ROS levels	Oxidative stress	Cytotoxic mechanism	Controlled increase (tumor-specific)

E. EPIGENOMIC BIOMARKERS (RESISTANCE & PLASTICITY)

Biomarker	Function	SCF Role	Endpoint
DNA methylation patterns	Tumor adaptability	Resistance tracking	Stability vs drift
Histone acetylation (H3K27ac)	Gene activation	Plasticity marker	Treatment-induced shifts
miRNA panel (miR-21, miR-10b)	Oncogenic regulation	Network control	Early relapse indicator

F. IMMUNOLOGIC BIOMARKERS (MICROENVIRONMENT CONTROL)

Biomarker	Function	SCF Role	Endpoint
IL-6, TNF-α	Inflammation	Tumor support	Reduction = efficacy
CD8+ T cell infiltration	Immune activation	Anti-tumor immunity	Increased infiltration
PD-L1 expression	Immune evasion	Resistance node	Downregulation desired
Microglial activation markers	CNS immune state	Neuroimmune axis	Stabilization indicator

G. NEUROFUNCTIONAL BIOMARKERS (CNS-SPECIFIC ENDPOINTS)

Biomarker	Modality	SCF Role	Endpoint
EEG (gamma coherence)	Electrophysiology	Neural stability	Preservation/recovery
Functional MRI (fMRI)	Connectomics	Neural integrity	Reduced tumor interference
Neurocognitive testing	Clinical	Functional outcome	Cognitive stabilization

H. IMAGING BIOMARKERS (PRIMARY CLINICAL ENDPOINT)

Modality	Biomarker	Endpoint
MRI (T1 + contrast)	Tumor volume	Primary endpoint (RANO criteria)
MRI perfusion	Blood flow	Anti-angiogenic effect
Diffusion-weighted imaging	Cell density	Tumor necrosis
PET (FDG)	Glucose uptake	Metabolic suppression

IV. SCF BIOMARKER INTEGRATION MATRIX

Tri-Axis Mapping (Aligned to API Design)

Axis	Mechanism	Biomarker Cluster
Axis 1	Signaling inhibition	p-AKT, mTOR, NF-κB
Axis 2	Metabolic collapse	ATP, lactate, NAD+/NADH
Axis 3	Cytotoxic/angiogenic suppression	VEGF, ROS, caspase-3

V. PRIMARY & SECONDARY ENDPOINT STRUCTURE

Primary Endpoints (FDA-Aligned)

Tumor volume reduction (MRI, RANO criteria)
Progression-Free Survival (PFS)
Overall Survival (OS)

Secondary Endpoints

Reduction in PI3K–AKT–mTOR signaling (proteomics)
Decrease in VEGF (angiogenesis suppression)
Metabolic collapse (ATP ↓, lactate ↓)
Increased apoptosis (caspase-3 ↑)

Exploratory Endpoints

Neural preservation (EEG, fMRI)
Immune reprogramming (CD8+, cytokines)
Epigenetic stabilization

VI. SCF SYNERGY-VALIDATED BIOMARKER CLUSTERS

Cluster	Combined Readout	Interpretation
Metabolic Collapse Cluster	ATP ↓ + Lactate ↓ + NAD+/NADH ↑	Tumor energy failure
Anti-Angiogenic Cluster	VEGF ↓ + MRI perfusion ↓	Vascular suppression
Cytotoxic Cluster	ROS ↑ + Caspase-3 ↑	Tumor apoptosis
Resistance Barrier Cluster	Stable methylation + low PD-L1	Reduced escape potential

Aligned with SCF synergy metrics (TSSM, SV-EQ, MGIS, SPCI)

VII. CLINICAL IMPLEMENTATION PROTOCOL

Sampling Schedule

Phase	Biomarkers
Baseline	Genomic, imaging, metabolic
Week 2–4	Transcriptomic, proteomic
Month 2–3	Imaging + metabolomic
Ongoing	Immune + neurofunctional

Companion Diagnostics

Liquid biopsy (ctDNA)
CSF biomarker profiling
Imaging-based AI quantification

VIII. FINAL PANEL SUMMARY

Category	Status
Coverage	Full multi-omic
Specificity	Glioblastoma-targeted
Mechanistic Alignment	Full SCF tri-axis
Regulatory Readiness	IND-compatible
Endpoint Strength	High (primary + surrogate validated)

MASTER REGISTRY INDEX

SCF-API-TGX-0001-GBM — THOGALINEX™ Glioblastoma API
SCF-BIO-PANEL-GBM-0001 — SCF Biomarker Panel (Glioblastoma)
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-PATH-EXT-0001 — SCF Pathophysiology Protocol
SCF-FDA-REG-0001 — FDA Drug Approval Processes

If desired, the next step is to generate the SCF Clinical Trial Design (Phase I–III) with biomarker-driven adaptive endpoints, which will directly operationalize this panel into an IND-ready protocol.